WO2017142368A2 - Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire - Google Patents

Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire Download PDF

Info

Publication number
WO2017142368A2
WO2017142368A2 PCT/KR2017/001808 KR2017001808W WO2017142368A2 WO 2017142368 A2 WO2017142368 A2 WO 2017142368A2 KR 2017001808 W KR2017001808 W KR 2017001808W WO 2017142368 A2 WO2017142368 A2 WO 2017142368A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
allergic
composition
present
dermatitis
Prior art date
Application number
PCT/KR2017/001808
Other languages
English (en)
Korean (ko)
Other versions
WO2017142368A3 (fr
Inventor
한명관
오유근
Original Assignee
전북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교 산학협력단 filed Critical 전북대학교 산학협력단
Priority claimed from KR1020170021592A external-priority patent/KR20170098182A/ko
Publication of WO2017142368A2 publication Critical patent/WO2017142368A2/fr
Publication of WO2017142368A3 publication Critical patent/WO2017142368A3/fr

Links

Images

Definitions

  • the present invention relates to a composition for the prophylaxis or treatment of allergic or inflammatory skin diseases comprising NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • Itching is a dermatological symptom with severe pain that increases the feeling of scratching and is a representative symptom of atopic dermatitis, contact dermatitis, urticaria and various skin diseases. Severe itching in skin diseases, along with secondary exacerbations such as sleep disorders, emotional instability, and irritable stress reactions, not only have a significant effect on the quality of life of the same patients, but also lead to a vicious cycle of the disease itself. It also causes significant levels of social and psychological distress for those around them.
  • the skin is composed of three layers from the outside, epidermis, dermis and subcutaneous fat layer.
  • the skin is the largest organ in the body and is exposed outside, making it easy to recognize the itching caused by external stimuli or internal lesions on the skin.
  • keratinocytes which form one component of the epidermis, secrete various types of inflammatory cytokines, interleukin, TNF-a, interferon, and chemokine, which are known as immune response regulators. Reacts sensitively to stimuli. For this reason, various diseases accompanied by itching occur frequently on the skin.
  • Atopic dermatitis is a chronic inflammatory disease with aggravation and remission, which is caused by multifactorial factors such as immunological dysfunction and exposure to allergens.
  • Repeated scratching of skin lesions caused by the severe itching of atopic dermatitis worsens dermatitis with the collapse of the skin barrier. Therefore, controlling the scratching behavior due to itching or itching will be an important and effective treatment for atopic dermatitis. Itching is accompanied by a wound, which is accompanied by wounds caused by bacterial infection and secondary allergens caused by external allergens.
  • the present inventors have made efforts to develop a new drug which is excellent in preventing or treating allergic or inflammatory skin diseases without any side effects, and as a result, NED19, bromo-cyclic ADP-ribose, and emodine have a histamine dependency and a histamine ratio.
  • the present invention was completed by confirming that not only dependent itching but also an improvement effect on various allergic or inflammatory skin diseases such as itching by atopic dermatitis is excellent.
  • Another object of the present invention is to provide a method for preventing or treating allergic or inflammatory skin diseases, comprising administering NED19, bromo-cyclic ADP-ribose, or emodine to a subject in need thereof.
  • Still another object of the present invention is to provide a composition for alleviating or suppressing itching, including NED19, bromo-cyclic ADP-ribose, or emodine as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the present invention provides a skin external preparation for the prevention or treatment of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the present invention provides a health food composition for the prevention or improvement of allergic or inflammatory skin diseases comprising NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the present invention also provides a method for preventing or treating allergic or inflammatory skin diseases, comprising administering NED19, bromo-cyclic ADP-ribose, or emodine to a subject in need thereof.
  • the present invention provides a cosmetic composition for alleviating or suppressing itching, including NED19, bromo-cyclic ADP-ribose, or emodine as an active ingredient.
  • the present invention also provides a method for alleviating or suppressing itching, comprising administering NED19, bromo-cyclic ADP-ribose, or emodine to a subject in need thereof.
  • NED19, bromo-cyclic ADP-ribose and emodine of the present invention are excellent in the prevention and treatment of various allergic or inflammatory skin diseases, including not only histamine-dependent and histamine-independent itch, but also itch caused by atopic dermatitis, It can be variously used as medicine, external skin preparation, food and cosmetics.
  • 1 is a diagram showing the effect of NED19 on the relief of histamine induced itch.
  • FIG. 2 is a diagram showing the effect of bromo-cyclic ADP-ribose on chloroquine induced itch relief.
  • FIG. 3 is a diagram showing the effect of emodin on the histamine induced itching relief.
  • FIG. 4 is a diagram showing the effect of emodine on chloroquine induced itch relief.
  • FIG. 5 is a diagram showing the effect of emodin on the itch relief by atopic dermatitis.
  • the present invention provides a composition for the prevention or treatment of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the composition includes a pharmaceutical composition, a topical skin composition and a nutraceutical composition.
  • the present invention also provides a method for preventing or treating allergic or inflammatory skin diseases, comprising administering NED19, bromo-cyclic ADP-ribose, or emodine to a subject in need thereof.
  • the present invention provides a pharmaceutical composition for the prophylaxis or treatment of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the active ingredient NED19 includes both trans-NED19 or cis-NED19, but is not limited thereto.
  • the active ingredient NED19 ((1R, 3S) -1- [3-[[4- (2-Fluorophenyl) piperazin-1-yl] methyl] -4-methoxyphenyl] -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b] indole-3-carboxylic acid) may be represented by the following Chemical Formula 1.
  • bromo-cyclic ADP-ribose (8-bromo-cyclic adenosine diphosphate ribose)
  • formula (2) the active ingredient bromo-cyclic ADP-ribose (8-bromo-cyclic adenosine diphosphate ribose)
  • the active ingredient emodin (emodin) may be represented by the following formula (3).
  • NED19, bromo-cyclic ADP-ribose, or emodine may be purchased commercially or directly synthesized, but are not limited thereto.
  • the compounds of the present invention can be prepared with pharmaceutically acceptable salts and solvates according to methods conventional in the art.
  • Pharmaceutically acceptable salts of the compounds of the invention include, but are not limited to, salts of acidic or basic groups that may be present in the compounds of the invention.
  • prevention means any action that prevents the disease by eliminating or early detecting the etiology of allergic or inflammatory skin disease.
  • treatment means all the actions that improve or beneficially change the symptoms caused by allergic or inflammatory skin diseases by the composition of the present invention.
  • allergy and inflammation are one of the defense reactions of biological tissues
  • the allergy is a sudden change in the ability to react in vivo when the organism comes in contact with any foreign substance, that is, the antigen antibody reaction occurs, the response It is said to be sensitive.
  • inflammation refers to complex lesions that involve three types: tissue degeneration, circulatory disorders and exudates, and tissue proliferation.
  • allergic or inflammatory skin diseases are atopic dermatitis, allergic dermatitis, contact dermatitis, acne. , Seborrheic dermatitis, sweat, urticaria or psoriasis, more preferably atopic dermatitis, contact dermatitis or itching, but the present invention is not limited thereto.
  • NED19, bromo-cyclic ADP-ribose and emodine of the present invention are excellent in the prevention and treatment of various allergic or inflammatory skin diseases, including not only histamine-dependent and histamine-independent itch, but also itch caused by atopic dermatitis, It can be variously used as medicine, external skin preparation, food and cosmetics.
  • the composition may further include one or more known active ingredients having an allergic or inflammatory skin disease prevention or treatment effect together with NED19, bromo-cyclic ADP-ribose, and emodine.
  • the composition may further comprise a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives are starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, hydrogen phosphate Calcium, lactose, mannitol, syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, Calcium stearate, white sugar and the like can be used.
  • the pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition, but is not limited thereto.
  • the composition can be administered in various oral or parenteral dosage forms during actual clinical administration, and when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used, or Excipients can be formulated and suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA.
  • diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used, or Excipients can be formulated and suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA.
  • Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil and the like.
  • the solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or sucrose. It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium styrate talc are also used.
  • the liquid preparations for oral administration include suspensions, solvents, emulsions, syrups, etc.
  • various excipients for example, wetting agents, sweeteners, fragrances, preservatives, etc. This may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the parenteral administration may be made using external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.
  • the term "administration" means providing a subject with a composition of the present invention in any suitable manner.
  • the preferred dosage of the composition depends on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the NED19, bromo-cyclic ADP-ribose and emodine of the present invention may be administered in an amount of 0.1 to 10000 mg / kg body weight per day.
  • Administration of the composition may be administered once a day, may be divided several times.
  • the composition can be administered to the subject by various routes. All modes of administration can be envisaged, for example, can be administered by oral, rectal or intravenous, intramuscular or subcutaneous injection, and can be administered by any route of application to the skin.
  • the composition may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of allergic or inflammatory skin diseases.
  • the present invention provides a skin external preparation for the prevention or treatment of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • the composition may further contain one or more known active ingredients having a prophylactic or therapeutic effect of allergic or inflammatory skin diseases together with NED19, bromo-cyclic ADP-ribose or emimodine.
  • the composition is not particularly limited in its formulation according to the desired body part, it may be prepared in any formulation conventionally prepared with reference to the known art.
  • liquids, ointments, creams, lotions, sprays, patches, oils, waxes, emulsions, suspensions, gels or aerosols may be used in the form, but is not limited thereto.
  • the composition may include conventional additives, for example, preservatives, solvents to aid the penetration of medicines, softeners in the case of ointments and creams, etc., may contain a conventional carrier such as ethanol or oleyl alcohol. have.
  • the composition is not limited to the above-described components, and may include other components blended with a conventional cosmetic composition or a pharmaceutical composition, if necessary.
  • a conventional cosmetic composition or a pharmaceutical composition for example, fats and oils, moisturizers, emollients, surfactants, organic or inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation promoters, Coolants, limiting agents, purified water, and the like.
  • the present invention provides a dietary supplement for the prevention or improvement of allergic or inflammatory skin diseases, including NED19, bromo-cyclic ADP-ribose or emodine as an active ingredient.
  • health functional food refers to a food having a bioregulatory function, such as prevention and improvement of disease, biodefence, immunity, recovery from illness, and inhibition of aging, and should be harmless to the human body when taken in the long term. .
  • the NED19, bromo-cyclic ADP-ribose or emodine when the substance is used as a food additive, the NED19, bromo-cyclic ADP-ribose or emodine may be added as it is or may be used together with other food or food ingredients, and according to a conventional method. Can be used.
  • the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • NED19, bromo-cyclic ADP-ribose or emodine is added in an amount of up to 15% by weight, preferably up to 10% by weight based on the raw material in the manufacture of food or beverage.
  • the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • the kind of the food there is no particular limitation on the kind of the food.
  • foods to which the substance may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gum, ice cream, various soups, beverages, teas, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
  • the composition may include various flavors or natural carbohydrates and the like as an additional component, as in the usual beverage.
  • the natural carbohydrates described above may be used as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclodextrin, and synthetic sweeteners such as saccharin and aspartame.
  • the proportion of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And carbonating agents used in the carbonated beverage.
  • the composition of the present invention may include a pulp for the production of natural fruit juice, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention provides a cosmetic composition for alleviating or suppressing itching, including NED19, bromo-cyclic ADP-ribose, or emodine as an active ingredient.
  • the present invention also provides a method for alleviating or suppressing itching, comprising administering NED19, bromo-cyclic ADP-ribose, or emodine to a subject in need thereof.
  • the composition may further contain at least one known active ingredient having an itch relieving or suppressing effect together with NED19, bromo-cyclic ADP-ribose or emodine.
  • the itch is also called pruritus, an unpleasant sensation that causes a desire to scratch or rub the skin, which is a symptom commonly observed in skin diseases. Itching is not particularly limited in the cause or form of the cause, in particular, itching referred to in the present invention is atopic dermatitis, allergic dermatitis, contact dermatitis, dermatitis due to roughness of the skin, acne, seborrheic dermatitis, sweat band, erosion, It includes all of the itch caused by one or more from the group consisting of frostbite, urticaria and psoriasis.
  • the composition can improve the skin barrier by inducing skin moisturization or skin hyperkeratosis through the improvement of the itch, it is characterized by having a skin condition improvement effect accordingly.
  • the composition is in addition to NED19, bromo-cyclic ADP-ribose or emodine, in addition to fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, commonly used in cosmetic compositions, Suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes It may further contain auxiliaries commonly used in the field of cosmetics or dermatology, such as pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients conventionally used in cosmetics. In addition, the above components may be introduced in an amount generally used in the field of dermatology.
  • the composition may be prepared in the form of a general emulsion formulation and solubilized formulation.
  • Cosmetics of the emulsified formulations include nutrient cosmetics, creams, essences, etc., and cosmetics of the solubilized formulations are flexible cosmetics.
  • the cosmetic composition of the present invention is an emulsion, suspension, emulsion, microemulsion, microcapsules, microgranules or ionic (liposomes) obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase.
  • ionic vesicle dispersants creams, skins, lotions, powders, sprays, pastes, packs, face washes, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, waxes, foundations or concealed sticks Can be provided. It may also be prepared in the form of a foam or in the form of an aerosol further containing a compressed propellant.
  • the carrier component is animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, oxidation Zinc and the like.
  • the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, and the like, in particular, in the case of a spray, additionally chlorofluoro Propellants such as rohydrocarbon, propane / butane, dimethyl ether, and the like.
  • a carrier component may include a solvent, a solubilizer, an emulsifier, and the like, and specifically, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycols, fatty acid esters of sorbitan, and the like.
  • a carrier diluent such as water, ethanol, propylene glycol
  • Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • the formulation of the composition is a surfactant-containing cleansing
  • a carrier component an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, methyltaurate, and sarcosy Acetates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, and the like.
  • the compounding component which may be added other than this is not limited to this, although any said component can be mix
  • NED19 represented by the following Chemical Formula 1 was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA) (Cat. No. sc-362814).
  • Bromo-cyclic ADP-ribose represented by the following formula (2) was purchased from Sigma (Sigma, Catalog # B5416).
  • Emodine represented by the following formula (3) was purchased from Sigma (Sigma, Catalog # E7881).
  • mice All animal experiments were performed according to the guidelines of the Experimental Animal Steering Committee of Chonbuk National University. Balb / c mice, 6-8 weeks old, were purchased from Orient Laboratory Animals (Seoul, Korea). Mice were maintained in an environment of 21-24 ° C., repeated 12 hours light cycle, and freely supplied with water and diet.
  • NED19 had an excellent effect of alleviating the itching caused by histamine in a concentration-dependent manner.
  • Br-cADPR has an excellent effect of alleviating itch by chloroquine, that is, histamine-independent itch.
  • mice were placed in a chamber (11 cm x 11 cm, 18 cm high) and photographed by video, and the number of scratches was measured using the hind legs. The results are shown in FIG.
  • the emodine has an excellent effect of alleviating the itch caused by chloroquine, that is, the histamine-independent itch, in a concentration-dependent manner.
  • atopic dermatitis was induced in mice using DNCB. Specifically, the right ear was shaved to remove hair, and then 20 ⁇ l of a 1% solution of DNCB dissolved in olive oil: ethanol (1: 4 volume ratio) was applied to sensitization. After 7 days, 10 ⁇ l of 0.5% DNCB was applied to the same ear. Next, the emodine of Example 3 was dissolved in DMSO and physiological saline to prepare a concentration of 0.1-10 ⁇ M, and then 20 ⁇ l of each solution was applied to the right ear once after 10 minutes of the last DNCB treatment for 1 hour. The number of scratches was measured. For the negative control, physiological saline was applied. The results are shown in FIG.
  • emodine has an excellent effect of alleviating the itch caused by atopic dermatitis in a concentration-dependent manner, and thus can be used as a therapeutic agent for atopic dermatitis.
  • the NED19, bromo-cyclic ADP-ribose, and emodine of the present invention have a prophylactic and therapeutic effect against various allergic or inflammatory skin diseases such as histamine dependent and histamine independent itch, as well as itch caused by atopic dermatitis.
  • excellent bar it can be used in a variety of medicines, external skin preparations, food and cosmetics.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • Vitamin B6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • Beta-1,3-Glucan 1.0%
  • Beta-1,3-Glucan 1.0%
  • Beta-1,3-Glucan 5.0%

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition permettant de prévenir ou de traiter une maladie allergique ou inflammatoire, comprenant un NED19, un ADP-ribose bromo-cyclique ou de l'émodine comme principe actif. Le NED19, l'ADP-ribose bromo-cyclique et l'émodine de la présente invention présentent un excellent effet dans la prévention et le traitement de diverses maladies cutanées allergiques ou inflammatoires, notamment du prurit dépendant de l'histamine et du prurit indépendant de l'histamine et du prurit lié à la dermatite atopique, et peuvent donc être utilisés de diverses manières dans des médicaments, des préparations cutanées externes, des aliments, des produits cosmétiques et similaires.
PCT/KR2017/001808 2016-02-19 2017-02-17 Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire WO2017142368A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160019807 2016-02-19
KR10-2016-0019807 2016-02-19
KR1020170021592A KR20170098182A (ko) 2016-02-19 2017-02-17 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물
KR10-2017-0021592 2017-02-17

Publications (2)

Publication Number Publication Date
WO2017142368A2 true WO2017142368A2 (fr) 2017-08-24
WO2017142368A3 WO2017142368A3 (fr) 2018-09-07

Family

ID=59625237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/001808 WO2017142368A2 (fr) 2016-02-19 2017-02-17 Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire

Country Status (1)

Country Link
WO (1) WO2017142368A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018070774A1 (fr) * 2016-10-11 2018-04-19 전북대학교 산학협력단 Utilisation d'antagonistes de cadpr ou de naadp
CN116747213A (zh) * 2023-06-30 2023-09-15 大连医科大学附属第一医院 大黄素在抑制皮脂腺合成与分泌中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828071D0 (en) * 1998-12-18 1999-02-17 Univ Bath Therapeutics
KR100812596B1 (ko) * 2006-12-15 2008-03-13 바이오스펙트럼 주식회사 천연 유래 화합물을 포함하는 피부보호 조성물
KR100832332B1 (ko) * 2007-02-12 2008-05-26 바이오스펙트럼 주식회사 아토피성 피부염 증상을 개선하기 위한 조성물
GB0811587D0 (en) * 2008-06-25 2008-07-30 Isis Innovation Novel Compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018070774A1 (fr) * 2016-10-11 2018-04-19 전북대학교 산학협력단 Utilisation d'antagonistes de cadpr ou de naadp
US11071748B2 (en) * 2016-10-11 2021-07-27 Industrial Cooperation Foundation Chonbuk National University Use of cADPR or NAADP antagonists
CN116747213A (zh) * 2023-06-30 2023-09-15 大连医科大学附属第一医院 大黄素在抑制皮脂腺合成与分泌中的应用

Also Published As

Publication number Publication date
WO2017142368A3 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
WO2017171491A1 (fr) Composition pharmaceutique comprenant un extrait de cellules souches pour la prévention ou le traitement d'une maladie inflammatoire
WO2017222317A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'éliminer la kératine cutanée, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant une ionone ou un sel de celle-ci comme ingrédient actif
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2010123184A1 (fr) Composition pour prévenir et traiter l'alopécie, à base de composés de norgalanthamine
WO2017213346A1 (fr) Composition contenant de la diosmine ou son sel comme ingrédient actif et présentant un effet d'amélioration de l'hydratation de la peau, d'exfoliation de la peau, de renforcement de l'élasticité de la peau, d'inhibition de l'érythème, de réduction des rides de la peau, ou de retardement du photovieillissement de la peau
WO2018004141A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'exfolier la peau, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant, en tant qu'ingrédient actif, un ou plusieurs composés choisis dans le groupe constitué du cimène, de l'acide béhénique, du 2-méthoxynaphtalène, du thymol et de leurs sels
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
WO2016159640A2 (fr) Composition anti-oxydante ou anti-vieillissement contenant du 5-adamantan-1-yl-n-(2,4-dihydroxybenzyl)-2,4-diméthoxybenzamide
WO2016093515A1 (fr) Composition pour activer un gène de longévité
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2016122091A1 (fr) Composition pharmaceutique pour la prévention et le traitement de maladie allergique ou de dermatite de contact, comprenant un extrait de cymbidium comme principe actif
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
WO2020256381A1 (fr) Composition de blanchiment de la peau comprenant en tant que principe actif de l'octadécène ou un sel de celui-ci
WO2012173383A2 (fr) Composition à usage externe pour l'épiderme, contenant en tant que principe actif du cryptotanshinone
WO2020130478A1 (fr) Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
WO2024080398A1 (fr) Peptide ayant des activités pour favoriser la croissance des cheveux et pour inhiber la chute des cheveux et son utilisation
WO2014185610A1 (fr) Composition pour prévenir la perte de cheveux ou favoriser la pousse des cheveux du fait de son contenu en extrait de son comme principe actif
WO2024080400A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux et supprimant la chute des cheveux et son utilisation
WO2024080401A1 (fr) Peptide favorisant la pousse des cheveux et inhibant la chute des cheveux et son utilisation
WO2013077617A1 (fr) Composition pour prévenir, traiter ou soulager la dermatite atopique, comprenant un immunosuppresseur et un inhibiteur de la transglutaminase 2
WO2023128630A1 (fr) Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara
WO2017142383A1 (fr) Composition et procédé pour prévenir ou traiter une maladie de la peau
WO2024080399A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux et inhibant la chute des cheveux et son utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17753529

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17753529

Country of ref document: EP

Kind code of ref document: A2